[go: up one dir, main page]

MX2020001958A - Procedimientos de diagnostico y tratamiento del cancer de pulmon. - Google Patents

Procedimientos de diagnostico y tratamiento del cancer de pulmon.

Info

Publication number
MX2020001958A
MX2020001958A MX2020001958A MX2020001958A MX2020001958A MX 2020001958 A MX2020001958 A MX 2020001958A MX 2020001958 A MX2020001958 A MX 2020001958A MX 2020001958 A MX2020001958 A MX 2020001958A MX 2020001958 A MX2020001958 A MX 2020001958A
Authority
MX
Mexico
Prior art keywords
pbmcs
lung cancer
treatment
diagnostic procedures
subject
Prior art date
Application number
MX2020001958A
Other languages
English (en)
Inventor
Fernando Patolsky
Giora Davidovits
David Eyal Davidovits
Irit Arbel
Shoval Tirman
Aviv Lutaty
Tali Scienmann
Reuven Tirosh
Soroka Hagit Peretz
Original Assignee
Savicell Diagnostic Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savicell Diagnostic Ltd filed Critical Savicell Diagnostic Ltd
Publication of MX2020001958A publication Critical patent/MX2020001958A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G01N33/5752—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G01N33/5758—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se proporciona un procedimiento de diagnóstico de cáncer de pulmón en un sujeto que lo necesite. Comprendiendo el procedimiento: (a) proporcionar una muestra biológica del sujeto que comprende células mononucleares de sangre periférica (PBMC); (b) poner en contacto in vitro las PBMC con un estimulante seleccionado del grupo que consiste en los estimulantes enumerados en las Tablas 3 y 4; y (c) medir la actividad metabólica de las PBMC que han sido puestas en contacto de acuerdo con (b), en el que un cambio estadísticamente significativo en la actividad metabólica de las PBMC en comparación con una muestra de control es indicativo de cáncer de pulmón.
MX2020001958A 2017-08-21 2018-08-20 Procedimientos de diagnostico y tratamiento del cancer de pulmon. MX2020001958A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762547906P 2017-08-21 2017-08-21
PCT/IL2018/050920 WO2019038761A1 (en) 2017-08-21 2018-08-20 METHODS FOR THE DIAGNOSIS AND TREATMENT OF LUNG CANCER

Publications (1)

Publication Number Publication Date
MX2020001958A true MX2020001958A (es) 2020-09-25

Family

ID=65439395

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001958A MX2020001958A (es) 2017-08-21 2018-08-20 Procedimientos de diagnostico y tratamiento del cancer de pulmon.

Country Status (11)

Country Link
US (3) US11619634B2 (es)
EP (1) EP3673267A4 (es)
JP (1) JP7356412B2 (es)
KR (1) KR102735890B1 (es)
CN (1) CN111133312A (es)
AU (1) AU2018320264B2 (es)
BR (1) BR112020003485A2 (es)
CA (1) CA3073254A1 (es)
IL (1) IL272810B2 (es)
MX (1) MX2020001958A (es)
WO (1) WO2019038761A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12035964B2 (en) * 2007-12-27 2024-07-16 Boston Scientific Medical Device Limited Electrosurgical pericardial puncture
KR102735890B1 (ko) 2017-08-21 2024-11-29 사비셀 다이아그노스틱 엘티디. 폐암을 진단 및 치료하는 방법
CN110517776B (zh) * 2019-08-16 2023-06-16 四川大学华西医院 一种老年人健康风险评估方法及其应用
CN114496239B (zh) * 2021-12-03 2024-05-14 汕头大学医学院附属肿瘤医院 肺癌sbrt放射性肺炎风险新型预测因子及其构建方法
KR20250152013A (ko) 2024-04-12 2025-10-22 중앙대학교 산학협력단 암 진단, 암 전이 진단, 또는 예후 예측용 조성물, 또는 암 예방, 치료, 또는 암 전이 억제용 약학적 조성물

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6451316B1 (en) 1998-10-05 2002-09-17 University Of Conneticut Health Center Methods for generating antigen-reactive T cells in vitro
CA2457667A1 (en) 2001-08-06 2003-06-26 Vanderbilt University Device and methods for monitoring the status of at least one cell
EP1537143A2 (en) 2002-09-05 2005-06-08 Cell Center Cologne GmbH Immunogenic muc1 glycopeptides
JP4625946B2 (ja) 2004-11-02 2011-02-02 国立大学法人 岡山大学 ｐＨ測定装置及びｐＨ測定方法
EP1736780A1 (en) 2005-06-24 2006-12-27 Eppendorf Array Technologies S.A. Method and means for detecting and/or quantifying hierarchical molecular change of a cell in response to an external stimulus
WO2008018905A2 (en) 2006-01-17 2008-02-14 Cellumen, Inc. Method for predicting biological systems responses
JP5107943B2 (ja) 2006-03-06 2012-12-26 ゼティク テクノロジーズ リミテッド 細胞の表現型を特定するための方法および組成物
US20100104572A1 (en) * 2006-11-02 2010-04-29 Sylvie Luria Methods for screening for therapeutic molecules and use of the molecules therefrom
EP2198021A4 (en) * 2007-08-24 2011-01-19 Oncotherapy Science Inc EBI3, DLX5, NPTX1, and CDKN3 for target genes of lung cancer therapy and diagnosis
US8476420B2 (en) * 2007-12-05 2013-07-02 The Wistar Institute Of Anatomy And Biology Method for diagnosing lung cancers using gene expression profiles in peripheral blood mononuclear cells
KR20110134482A (ko) * 2009-03-19 2011-12-14 도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬 Ｓｏｘ２ 유래의 ｈｌａ-ａ２４결합성 암 항원 펩티드
WO2011000572A1 (de) 2009-07-02 2011-01-06 Patenthandel Portfoliofonds I Gmbh & Co. Kg Verfahren und vorrichtung zum nachweis von biologischen langzeiteffekten in zellen
WO2011031803A1 (en) 2009-09-08 2011-03-17 Nodality, Inc. Analysis of cell networks
CN102906275A (zh) 2010-02-10 2013-01-30 加利福尼亚大学董事会 肺癌检测的唾液生物标记
CN103518133B (zh) 2011-04-06 2016-08-17 雷蒙特亚特特拉维夫大学有限公司 监测和分析代谢活性分布的方法及其诊断和治疗用途
US20140186363A1 (en) * 2011-06-03 2014-07-03 University Of Zurich Magea3 binding antibodies
SG11201602976XA (en) * 2013-10-22 2016-05-30 Univ Ramot Method and system for sensing
ITRM20130700A1 (it) * 2013-12-19 2015-06-20 Stichting Katholieke Univ Metodo per il rilevamento di cellule tumorali circolanti
KR102735890B1 (ko) 2017-08-21 2024-11-29 사비셀 다이아그노스틱 엘티디. 폐암을 진단 및 치료하는 방법

Also Published As

Publication number Publication date
JP2020531846A (ja) 2020-11-05
US12306188B2 (en) 2025-05-20
CN111133312A (zh) 2020-05-08
US20200355689A1 (en) 2020-11-12
IL272810A (en) 2020-04-30
KR20200056999A (ko) 2020-05-25
KR102735890B1 (ko) 2024-11-29
AU2018320264A1 (en) 2020-04-02
JP7356412B2 (ja) 2023-10-04
US20230228755A1 (en) 2023-07-20
CA3073254A1 (en) 2019-02-28
EP3673267A1 (en) 2020-07-01
BR112020003485A2 (pt) 2020-08-25
US20250244330A1 (en) 2025-07-31
IL272810B1 (en) 2025-06-01
IL272810B2 (en) 2025-10-01
US11619634B2 (en) 2023-04-04
WO2019038761A1 (en) 2019-02-28
AU2018320264B2 (en) 2024-08-15
EP3673267A4 (en) 2021-03-24

Similar Documents

Publication Publication Date Title
MX2020001958A (es) Procedimientos de diagnostico y tratamiento del cancer de pulmon.
MX2009011228A (es) Deteccion de niveles elevados de la proteina her-2/neu de celulas cancerosas circulantes no aisladas y tratamiento.
MX2007004079A (es) Detecci??n de niveles elevados de prote??na her-2/neu en celulas cancerosas circulantes y tratamiento.
AR051524A1 (es) Seleccion de pacientes para una terapia con un inhibidor de her
MX2020006715A (es) Anticuerpos especificos del heterodimero de cd3-delta/epsilon.
MX342791B (es) Ensayo elisa para la detección de vegf.
CL2017000546A1 (es) Análisis de coagulación universal microfluídico basado en chips
MX2018012771A (es) Sonda de oximetria con analisis de profundidad de tejido electronicamente seleccionable.
PE20200479A1 (es) Ensayos de diagnostico para detectar, cuantificar y/o rastrear microbios y otros analitos
MX342735B (es) Diagnostico acompañante para terapia con agente anti-hialuronano y metodos de uso del mismo.
EP4306636A3 (en) Monolayer of pbmcs or bone-marrow cells and uses thereof
BR112018012070A2 (pt) método para a produção de tecidos/ órgãos utilizando células sanguíneas
EA201590686A1 (ru) Тест на митохондриальную токсичность
MA38042B2 (fr) Méthylglyoxal en tant que marqueur du cancer
AU2018275891A1 (en) Articles of manufacture and methods related to toxicity associated with cell therapy
BR112016002709A2 (pt) queratinas como biomarcadores para câncer cervical e sobrevivência
ES2509567T3 (es) Identificación de variación genética en tejidos afectados
ES2570609T3 (es) Método para someter a ensayo la aminoacilasa 1 para el diagnóstico in vitro del cáncer colorrectal
BR112018076005A2 (pt) anticorpo monoclonal isolado, método para medir o nível de gama-glutamil-l-epsilon-lisina (ggel), método ex vivo para o monitoramento de apoptose, uso de um anticorpo monoclonal específico para gama-glutamil-l-epsilon-lisina (ggel), métodos para monitorar a eficácia de um tratamento indutor de apoptose, método de tratamento de uma doença associada a apoptose desregulada, kit para o monitoramento de apoptose, método de tratamento de sepse e dispositivo de imunoensaio de fluxo lateral
CL2021000002A1 (es) Método para la detección y el recuento epigenético de células inmunitarias en muestras de sangre humana para inmunodiagnóstico y exploración neonatal
ZA202002371B (en) Collection and preparation of blood samples for point-of-care diagnostics
EA201800413A1 (ru) Способ автоматического измерения вязкости крови
Pósfai et al. Thrombotic events and importance of IPSET thrombosis risk evaluation score in essential thrombocythaemia
RU2013105660A (ru) Способ прогнозирования стадии рассеянного склероза с учетом показателей биохимического статуса
QIN et al. Expression of interleukin-17 in peripheral blood mononuclear cells of patients with multiple myeloma